Search results
Results from the WOW.Com Content Network
On rare occasion, infarcts in the hippocampus or thalamus are the cause of dementia. [12] A history of stroke increases the risk of developing dementia by around 70%, and recent stroke increases the risk by around 120%. [13] Brain vascular lesions can also be the result of diffuse cerebrovascular disease, such as small vessel disease. [5]
Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. [14] It is indicated in the treatment of schizophrenia and schizoaffective disorder . [ 14 ] It is marketed by Janssen Pharmaceuticals .
A high score corresponds to a greater risk of stroke, while a low score corresponds to a lower risk of stroke. The CHADS 2 score is simple and has been validated by many studies. [ 2 ] In clinical use, the CHADS 2 score (pronounced "chads two") has been superseded by the CHA 2 DS 2 -VASc score ("chads vasc" [ 3 ] ), which gives a better ...
Researchers found that every change in these indicators was linked to an increased stroke risk of 10-19%. ... “Stroke remains a leading cause of disability and death globally, with many cases ...
The study found the score to be 31.6% sensitive in high-risk patients (score >5) and only 12.5% specific in low-risk patients (score ≤2). [ 7 ] Scoring system
Hemorrhagic stroke may occur on the background of alterations to the blood vessels in the brain, such as cerebral arteriolosclerosis, cerebral amyloid angiopathy, cerebral arteriovenous malformation, brain trauma, brain tumors and an intracranial aneurysm, which can cause intraparenchymal or subarachnoid hemorrhage.
The most common presentation of cerebrovascular disease is an ischemic stroke or mini-stroke and sometimes a hemorrhagic stroke. [2] Hypertension (high blood pressure) is the most important contributing risk factor for stroke and cerebrovascular diseases as it can change the structure of blood vessels and result in atherosclerosis . [ 5 ]
J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report. It sued Teva and Mylan, which ...